Celgene (CELG) Says Results from First Phase III Trial of Oral Ozanimod Versus an Active Comparator in Relapsing MS Presented at MSParis2017
Tweet Send to a Friend
Celgene Corporation (NASDAQ: CELG) today announced detailed results from the phase III SUNBEAM™ trial evaluating the efficacy and safety of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
